Logo

Roivant Launches New Vant to Develop Eisai’s RVT-2001 for Myelodysplastic Syndromes

Share this

Roivant Launches New Vant to Develop Eisai’s RVT-2001 for Myelodysplastic Syndromes

Shots:

  • Roivant’s launched new subsidiary, Hemavant, that entered into a licensing agreement with Eisai for exclusive global rights to RVT-2001 for the treatment of transfusion-dependent anaemia in patients with lower-risk myelodysplastic syndromes
  • Hemavant plans to develop RVT-2001 as an oral therapy with expected P-I/II study initiation in H1’22 with initial data expected in 2023
  • RVT-2001 showed RBC-TI rate of >30% in a P-I/II trial involving a subset of 19 patients with lower-risk, transfusion-dependent MDS, 15 out of 19 had prior treatment with BMS’ Revlimid (lenalidomide) and/or hypomethylating agents

 Ref: Roivant | Image: Fierce Biotech

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions